BMW set to increase stake in China’s Brilliance Automotive

By Sean Galea-Pace
Share
The automotive giant, BMW, has announced it will invest $4.16bn to increase its interest in Chinese company, Brilliance Automotive, in a move that will...

The automotive giant, BMW, has announced it will invest $4.16bn to increase its interest in Chinese company, Brilliance Automotive, in a move that will see its stake rise from 50% to 75%.

The Germany-based firm will also invest over $3.4bn to enhance its existing production capacity in China, BBC News reports.

As a result of the joint venture contract, the new agreement is valid for 22 years until 2040 and will further deepen the current successful collaboration between the two companies.

Since first beginning the joint venture in 2003, BMW Brilliance Automotive (BBA) has achieved significant success under the BMW brand in China with approximately 560,000 BMW brand vehicles delivered to customers in the country in just 2017 alone.

See more:

Harald Krüger, Chairman of the Board of Management of BMW AG, said: “We are consistently following our growth strategy for China. With continuous investment, as well as the development and production of electric vehicles, we underline China’s importance as a dynamic growth market for us.”

“Our success story goes hand in hand with the success of the joint venture BBA. Together with our partners, we contribute to the sustainable development of the Chinese market.”

In addition, the Chinese government hope to see at least 20% of cars sold to be electric or rechargeable-hybrid vehicles by 2025.

Share

Featured Articles

Axiado & Pegatron Partner to Boost Server Security

Axiado and Pegatron's collaboration enhances server security for manufacturing, delivering robust AI-driven protection for modern industrial data centres

Genus Power Showcases Smart Metering Innovation & Diversity

Genus Power impresses US delegation with cutting-edge smart metering technology and a diverse workforce, advancing global clean energy solutions

Telix's bid to Expand Access to Cancer Radiopharmaceuticals

Rhine Pharma, spun off by Telix, aims to open production to improve worldwide access to radiopharmaceuticals for cancer imaging & treatment

UK Automotive Manufacturers Face Net Zero Challenge

Sustainability & ESG

Samsung Biologics Secures US$1.24Bn Manufacturing Deal

Production & Operations

How is ABB Revolutionising Automotive Sustainability?

Sustainability & ESG